The Nanoparticle Drug Delivery Market

SUMMARY

Executive Summary

• AIM, SCOPE AND ORGANIZATION OF REPORT
• CIENTIFICA NANOTECHNOLOGY MODEL
  • Definitions of Nanotechnologies
  • Major Assumptions
• BACKGROUND

Aim, Scope and Organization of Report

This report will give Pharma investors a comprehensive understanding on the impact of nanotechnologies on the pharmaceutical market and companies, which include companies that are producing nanomaterials/technologies to enable better drug delivery compounds (drug delivery company) and companies that are using nano-enabled formulations to enhance drug delivery (drug formulation company).

This report will provide an in-depth discussion on recent developments of nanoparticleenabled drug delivery systems (DDS) and future opportunities. It is tailored for investors who plan to invest in the pharmaceutical industry with an eye towards how nanoparticle drug delivery technology will impact the economics of the pharmaceutical market.

The information includes business summaries, technology core competencies, how nanoparticle adds value for investors in drug delivery companies, comercialization strategies, intellectual property and available markets.

There are 58 case studies on nanoparticle DDS listed according to 3 categories:

• Delivery Method/Routes of administration
  • Oral administration
  • Transdermal delivery
  • Injectable delivery
  • Topical delivery
  • Inhaled/nasal/pulmonary delivery
  • Implantable delivery
• Therapeutics
  • Cancer therapy
  • Vaccines
  • Antibody
  • DNA-based therapy
• Technology
  • Nanoparticulate encapsulation
  • Dendrimer-based targeted therapeutics technology
  • Liposomes nanotechnology
  • Nanotube technologies
  • Nanoparticles coating technology
  • Silica-chitosan nanocomposite
  • Nanosome technology

TABLE OF CONTENTS

TABLE OF EXHIBITS

EXECUTIVE SUMMARY

• AIM, SCOPE AND ORGANIZATION OF REPORT
• CIENTIFICA NANOTECHNOLOGY MODEL
  • Definitions of Nanotechnologies
  • Major Assumptions
• BACKGROUND

MARKET FORECAST & OVERVIEW

INTRODUCTION TO THE MARKETS

• NANOPHARMACEUTICALS
• NANOTECHNOLOGY IN DRUG DELIVERY
• NANOBIOTECHNOLOGY IN DRUG DELIVERY
• OTHER APPLICATIONS FOR NANOMATERIALS IN THE MEDICAL AND PHARMACEUTICAL SECTOR
• TRENDS AND NEEDS
• ROADMAP
• NANOTECHNOLOGY INFLUENCE IN PHARMACEUTICAL VALUE CHAIN
• ANALYTICAL TECHNIQUES FOR NANOPARTILE DRUG DELIVERY
  • Properties
  • Production Of Nanoparticles
  • Measuring Dispersion Of Nanoparticles
  • Analysis Of Carrier Systems
• NANOPARTICLES AS DRUG CARRIERS
  • What Can Nanoparticles Do In Drug Delivery
  • Overview On The Types Of Nanoparticles In Drug Delivery
  • The First Nanoparticle Drug Delivery System Reaches The Market
  • Present And Future Applications
• PROJECTED PRODUCT PIPELINE FOR NANOPARTICLE IN DRUG DELIVERY MARKET
  • Overview Of Nanoparticle Drug Delivery System (DDS) In Various Applications
  • Available Applications Of Nanopartcile In Drug Delivery

DRUG DELIVERY CHALLENGES -- WHY DRUG DELIVERY & WHY NANOPARTICLES

• THE NEED FOR BETTER DRUG THERAPY
• THE NEED FOR DRUG SOLUBILITY
• THE NEED FOR SITE-SPECIFIC AND ORGAN-SPECIFIC IN FUNCTION

DRIVERS AND OPPORTUNITIES FOR NANOPARTICLE DRUG DELIVERY

• THE AIM OF DRUG TARGETING
• REASONS WHY THE DRUG DELIVERY MARKET IS RAPIDLY EXPANDING
• MARKET DRIVERS FOR ENHANCED DRUG DELIVERY
• THE ADVANTAGES OF USING POLYMERIC NANOPARTICLES (PNPS) IN DRUG DELIVERY
• EXPANDING GOVERNMENTAL FUNDING DRIVES THE NANOBIOTECHNOLOGY MARKET
• HOW DRUG COMPANIES ARE REACTING TO THIS EXPANSION

FUTURE BARRIERS AND CHALLENGES

• BIG PHARMACEUTICAL COMPANIES RELUCTANT TO INVEST IN UNTRIED TECHNOLOGIES
• LACK OF REGULATORY CASE LAW
• LONG ADMISSION PROCEDURES INCLUDING FOR EXAMPLE SEVERAL CLINICAL TRIALS
• A NEED FOR RAPID SCREENING METHODS
• SCALABILITY OF NANOPARTICLE PRODUCTION
• AN URGENT NEED FOR ANALYTICAL METHODS
• A NEED FOR THE INVESTIGATION OF FURTHER NANOPARTICLES
• THE POTENTIAL TOXICITY OF ENGINEERED NANOPARTICLES IS AN UNSOLVED ISSUE AND STILL NEEDS TO BE DEALT WITH
• THE FUTURE OF NANO AND BIO COLLABORATIONS IS PROMISING

NANOPARTICLE ADDED VALUE IN DRUG DELIVERY

• CASE STUDY -- UNIVERSITY OF MICHIGAN'S NANOPARTICLE-BASED PAIN RELIEF STUDY FOR MILITARY BATTLEFIELD USE
• CASE STUDY -- ACUSPHERE'S HYDROPHOBIC DRUG DELIVERY SYSTEM (HDDS™) FOR REFORMULATION OF HYDROPHOBIC DRUGS
• CASE STUDY -- IMARX'S HYDROPLEX™ PLATFORM FOR DELIVERING HYDROPHOBIC DRUGS
• CASE STUDY - ALPHARX'S NANOPARTICLE DRUG DELIVERY PLATFORM FOR ANTIBIOTIC DRUGS
• CASE STUDY - CYTRX'S RNAI NANOPARTICLE DELIVERY TECHNOLOGY FOR RNAI THERAPEUTICS

INVESTING IN NANOPARTCLE-ENABLED DRUG DELIVERY INDUSTRY

• CASE STUDY - NANOTHERAPEUTICS' COMMERCIALISATION STRATEGY
  • Business Summary
  • Technology Core Competency
  • Commercialisation Strategy
  • Available Market
• CASE STUDY - HOW CAN NANOVINDEX'S NANOPARTICLE HYDROGEL COMPOSITES ADD VALUE FOR DRUG DELIVERY INVESTORS
  • Business Summary
  • Technology Core Competency
  • How Nanoparticles Add Value For Investors In Drug Delivery Company
  • Comercialization Strategy
  • Available Market
• CASE STUDY -- KEYSTONE NANO'S MOLECULAR DOTS (MDS) COMMERCIALISATION STRATEGY
  • Business Summary
  • Technology Core Competency
  • How Nanoparticles Add Value For Investors In Drug Delivery Company
  • Commercialisation Strategy
  • Available Market
  • Intellectual Property
• CASE STUDY - NANOCARRIER'S PROTEINS NANOENCAPSULATION SEEKING OUT BIG BIOTECH BUSINESS
  • Business summary
  • Technology Core Competency
  • How Nanoparticles Add Value For Investors In Drug Delivery Company
  • Commercialisation Strategy
  • Available Market
• CASE STUDY -- NANOBIOMAGNETICS' BUSINESS MODEL FOR ORGAN-ASSISTING-DEVICE (OAD) TECHNOLOGIES
  • Business Summary
  • Technology Core Competency
  • How Nanoparticles Add Value For Investors In Drug Delivery Company
  • Commercialisation Stratety
  • Intellectual Property
• CASE STUDY - HOW CAN AVIDIMER THERAPEUTICS' AVIDIMERS PLATFORM TECHNOLOGY ADD VALUE FOR DRUG DELIVERY INVESTORS
  • Business Summary
  • Techonology Core Competency
  • How Nanoparticles Add Value For Investors In Drug Delivery Company
  • Commercialisation Strategy
• CASE STUDY -- CAPSULUTION'S COMMERCIALISATION STRATEGY FOR LBL-TECHNOLOGYR-BASED DRUG DELIVERY SYSTEMS
  • Business Summary
  • How Nanoparticles Add Value For Investors In Drug Delivery Company
  • Commercialisation Strategy
• CASE STUDY -- ACCESS PHARMACEUTICALS' PRODUCT PIPELINE FOR COBALAMIN™- MEDIATED DISEASE TARGETING
  • Business Summarry
  • Technology Core Competency
  • How Nanoparticle Add Value For Investors In Drug Delivery Company
• CASE STUDY - AZAYA THERAPEUTICS' PRODUCT PIPELINE FOR PROTEIN STABILIZED LIPOSOME (PSL™) NANOTECHNOLOGY
  • Business Summary
  • Technology Core Competency
  • Commercialisation Strategy

NANOPARTICLE DRUG DELIVERY SYSTEM BY DELIVERY METHOD/ROUTES OF ADMINISTRATION

• DELIVERY METHOD
• ORAL ADMINISTRATION
  • Case Study -- Access Pharmaceuticals' Cobalamin™ - Mediated Disease Targeting
  • Case Study - Nanotherapeutics' Nanoparticle Oral Applications
  • Case study - SoluBest's Solumer™ Technology Platform
• TRANSDERMAL DELIVERY
  • Case Study -- Biophan Technologies' Transdermal Patches By Using Halloysite Nanotubes Technology
  • Case Study -- The Interstitial NanoSystems' Transdermal Nanoparticle Delivery
• INJECTABLE DELIVERY
  • Case Study -- Biophan Technologies' Nanomagnetic Guided Drug Delivery
  • Case Study -- Nanobiotix's NanoBiodrugsTM
• TOPICAL DELIVERY
  • Case Study -- Starpharma's VivaGel™
  • Case Study - Nanotherapeutics' NanoDRY™; NanoCOAT™ and NanoQUAD™ Drug Delivery Systems
• INHALED/NASAL/PULMONARY DELIVERY
  • Case Study -- Interstitial NanoSystem's Pulmonary Nanoparticle Delivery
• IMPLANTABLE DELIVERY
  • Case Study -- Biophan Technologies' Nanomagnetic Drug Delivery: Drug-Eluting Implanted Devices
  • Case Study -- NanoBioMagnetics' Organ-Assisting-Device (OAD) Technologies

NANOPARTICLE DRUG DELIVERY SYSTEM BY THERAPEUTICS

• THERAPY
• CANCER THERAPY
  • Case Study -- Nanocarrier's Micellar Nanoparticles And Key Delivery Systems
  • Case Study -- Abraxis BioScience's Nanoparticle Albumin Bound (nabTM) Technology Platform
  • Case Study -- Abraxis BioScience's AbraxaneR
  • Case Study -- Access Pharmaceuticals, Inc
  • Case Study -- Advance Nanotechnologies' Nanoparticle Composites Drug Delivery System
  • Case Study -- BioAlliance Pharma's Nanoparticle-based TransdrugR Drug Delivery Platform
  • Case Study -- Cornerstone Pharmaceuticals' Emulsiphan™ Nanoparticle Tumor Targeting Technology
  • Case Study -- Insert Therapeutics' Nanoparticle Mediated Drug Delivery System
  • Case Study -- Keystone Nano's Molecular Dots (MDs) Drug Delivery Technology
  • Case Study -- Magforce Nanotechnologies' MagForceR Nanoparticles
  • Case Study -- Tempo Pharmaceuticals' Nanocell™ Technology
  • Case Study -- Aphios Corporation's TaxosomesTM
• VACCINES
  • Case Study -- Biosante Pharmaceuticals' Calcium Phosphate Nanoparticles (CAP)-based Technology
  • Case Study -- NanoMed's Nanotemplate Engineering Technology
  • Case Study -- Novavax's Micellar Nano Particles (MNPs), NovasomeR Paucilamellar Vesicles And Virus-Like Particle (VLP) Technology
• ANTIBODY
  • Case Study -- Ablynx's NanobodyR Platform
  • Case Study - NanoViricides' Targeted Anti-Viral Therapeutics Platform
• DNA BASED THERAPY
  • Case Study -- Introgen Therapeutics' Nanoparticle Drug Delivery Technology Platform
  • Case Study -- Asklepios BioPharmaceutical Inc
  • Case Study -- Copernicus Therapeutics' DNA Nanoparticles
  • Case Study -- Calando Pharmaceuticals' Targeted Polymeric Nanoparticle Delivery Systems And Sirna Design
  • Case Study -- Epeius Biotechnologies' Targeted Delivery System (TDS) Technology
  • Case Study -- Intradigm's Nanoparticle-Based Delivery System
  • Case Study -- Flamel Technologies' MedusaR Delivery Platform
  • Case Study -- Novosom AG's SMARTICLESR and CAGICLESR Technology
  • Case Study -- Transgenex Nanobiotech's SiPlex™ Technology

NANOPARTICLE DRUG DELIVERY SYSTEM BY TECHNOLOGY

• NANOPARTICULATE ENCAPSULATION
  • Case Study -- Aquanova's Nanoparticulate Encapsulation Technology
  • Case Study -- Bio Delivery Sciences International's BioralR Encochleation Drug Delivery Technology
  • Case Study -- Capsulution's LBL-TechnologyR-based Drug Delivery Systems
  • Case Study -- Ceramisphere's Encapsulation Technology
  • Case Study - Genesegues' Targeted Nanocapsule Technology
  • Case Study - iCeutica's Encapsulated Organic Nanoparticles (EON™) Platform
  • Case Study - NutraLease's Nanoencapsulation Technology
• THE DENDRIMER-BASED TARGETED THERAPEUTICS TECHNOLOGY
  • Case Study -- Avidimer Therapeutics' Avidimers
  • Case Study -- Dendritic Nanotechnologies Inc
• LIPOSOMES NANOTECHNOLOGY
  • Case Study -- Azaya Therapeutics' Protein Stabilized Liposome (PSL) Nanotechnology Platform
  • Case Study -- LiPlasome Pharma's Liposome-based Drug Delivery Platform
• NANOTUBE TECHNOLOGIES
  • Case Study -- Biophan Technologies' Halloysite Nanotube Technologies
  • Case Study -- NanoCyte's Nanotube Technology-based Drug Delivery System
• NANOSHELL TECHNOLOGY
  • Case Study -- Nanospectra Biosciences' AuroLase™ Cancer Therapy
• NANOPARTICLES COATING TECHNOLOGY
  • Case Study -- Cytimmune's Colloidal Gold Nanoparticle-Based Delivery Platform
• SILICA-CHITOSAN NANOCOMPOSITE
  • Case Study -- ISTN's Silica-Chitosan Nanocomposties For Peptic Ulcer Treatment
• NANOCRYSTAL TECHNOLOGY
  • Case Study -- Elan's NanoCrystalR Technology
• NANOSOME TECHNOLOGY
  • Case Study -- Molecular Therapeutics' Nanosome Platform
• NANOSUSPENSION TECHNOLOGY
  • Case Study -- Baxter BioPharma Solutions' NANOEDGE Dispersion Technology
• POLYMER THERAPEUTICS
  • Case Study - Labopharm's Polymeric Nano-Delivery System™
  • Case Study -- Intezyne Technologies' IVECT™ Drug Delivery Platform (DDP)
  • Case Study -- Insert Therapeutics' Nanoparticle Mediated Drug Delivery System
• APPENDIX 1: LIST OF NANOPARTICLE DRUG DELIVERY PLATFORMS/TECHNOLOGIES
• APPENDIX 2: NANOPARTICLES IN DRUG DELIVERY PRODUCTS ON THE MARKET OR IN CLINICAL PHASE 1/2/3
• APPENDIX 3: OVERVIEW OF NANOPARTICLE APPLICATIONS IN DRUG DELIVERY
• APPENDIX 4: DRUG DELIVERY COMPANY - COMPANIES WHO PRODUING NANOPARTICLES/TECHNOLOGIES ENABLE BETTER DRUG DELIVERY COMPOUNDS
• APPENDIX 5: DRUG FORMULATION COMPANY - COMPANIES WHO USING NANOPARTICLE-ENABLED FORMULATIONS TO ENHANCE DRUG DELIVERY

Table of Exhibits

• Exhibit 1: Nanoparticle Drug Delivery System By Delivery Method/Routes Of Administration
• Exhibit 2: Nanoparticle Drug Delivery System By Therapeutics
• Exhibit 3: Nanoparticle Drug Delivery System By Technology
• Exhibit 4: Nanoparticle Drug Delivery Technology Used By Drug Formulation Company And Drug Delivery Company By Nation
• Exhibit 5: Phama R&D Spend On Nanotech
• Exhibit 6: Share Of DDS Market
• Exhibit 7: Value Of Nanotechnology Based DDS 2006-2012
• Exhibit 8: Value Of Nanotechnology Based DDS 2006-2015
• Exhibit 9: Value Of Nanotechnology Based DDS 2006-2015
• Exhibit 10: Share of DDS Market
• Exhibit 11: Impace Of Nanotechnologies On Drug Delivery Market 2006-2015
• Exhibit 12: Value Of Nanotparticle Based DDS 2006-2012
• Exhibit 13: Value Of Nanotparticle Based DDS 2006-2015
• Exhibit 14: Value Of Nanostructure Based DDS 2006-2012
• Exhibit 15: Value Of Nanostructure Based DDS 2006-2015
• Exhibit 16: Value Of Dendrimer Based DDS 2006-2012
• Exhibit 17: Value Of Dendrimer Based DDS 2006-2015
• Exhibit 18: Future Medical Practice Estimations Within The Drug Encapsulation/Drug Delivery/Drug Targeting Sector
• Exhibit 19: Estimated Global Production Rates For Various Nanomaterials And Devices (2003- 2004)
• Exhibit 20: Average Technology Targets Of Nanoparticles In The Pharmaceutical Sector
• Exhibit 21: Future Development Of Diagnostics And Therapy By The Means Of Advanced Medical Tools
• Exhibit 22: Nanotechnology Implications On Medical Sector
• Exhibit 23: Pharmaceutical Value Chain And Involvement Of The Four Technologies
• Exhibit 24: Drug Encapsulation/Drug Delivery/Drug Targeting
• Exhibit 25: Typical Image of Colloidal Gold Nanoparticles
• Exhibit 26: FDA Approved Nanoparticle DDS
• Exhibit 27: The Most Appropriate Types of Nanoparticles for Drug Delivery
• Exhibit 28: Overview On The Most Appropriate Types Of Nanoparticles Used In Drug Encapsulation/Drug Delivery/Drug Targeting
• Exhibit 29: Schematic Representation of Polymer Therapeutics Now In or Progressing Towards Clinical Development
• Exhibit 30: Schematic Illustration Of The Therapeutics And Technologies In Clinical Development And/Or On The Market As Treatment For Cancer That Can Be
• Viewed As Nanomedicines
• Exhibit 31: Trend In Issued Patent Involving Nanoparticles For Drug Delivery (1992- 2004)
• Exhibit 32: Goal Of Select Nanoparticle Drug Delivery Patents Issued During 1992-2004
• Exhibit 33: Most Important Applications Of Nanotechnology In The Medical Sector
• Exhibit 34: Typical Configurations Utilised In Nanoparticles Applied To Medical Or Biological Problems
• Exhibit 35: Nanoparticles As Imaging Agents And Drug Carriers
• Exhibit 36: A Representative Photograph of Nanoparticles
• Exhibit 37: World Nanotechnology Industry Focus In 2004 By Sector -- Nanobiotechnology Companies Represent Around 8% Of The Overall Industry
• Exhibit 38: Summary Of Application Areas For Nanoscale Pharmaceuticals And Medicine In Drug Delivery
• Exhibit 39: Trend In Issued Patent Involving Nanoparticle
• Exhibit 40: Expected Evident Bottlenecks In R&D In Drug Encapsulation/Drug Delivery/Drug Targeting
• Exhibit 41: Expected Barriers In The Development Of Particular Types Of Nanoparticles
• Exhibit 42: Specified Expected Barriers In The Development Of Particular Types Of Nanoparticles
• Exhibit 43: The Representation Of HydroPlex™
• Exhibit 44: Slow Releasing Feature Of Encapsulated G-CSF
• Exhibit 45: NanoCarrier Product Pipeline
• Exhibit 46: Business Model of NanoCarrier
• Exhibit 47: NanoBioMagnetics' Investor Business Model
• Exhibit 48: Avidimer Therapeutics' Avidimers Technology
• Exhibit 49: Avidimer Therapeutics' Avidimers Technology
• Exhibit 50: Access Pharmaceuticals Product Pipeline
• Exhibit 51: Azaya Therapeutics Product Pipeline
• Exhibit 52: Access Pharmaceuticals' Cobalamin™
• Exhibit 53: Cobalamin™ Mechanism of Absorption
• Exhibit 54: A Study Of The Oral Administration Of Cobalamin™-Coated Nanoparticles Compared To Uncoated Nanoparticles In Rodents
• Exhibit 55: The Effectiveness Of Oral Drug Delivery Using Cobalamin™-Coated Nanoparticles
• Exhibit 56: Biophan Technologies' Transdermal Patch
• Exhibit 57: Rendering Of Nanotech-Based Bandage
• Exhibit 58: Interstitial NS Transdermal Delivery Applicator Prototype
• Exhibit 59: Biophan Technologies' Nanomagnetic Particle
• Exhibit 60: Injected Drug
• Exhibit 61: Drug Drawn To Tumor
• Exhibit 62: Activating Drug In Tumor
• Exhibit 63: Nanobiotix's NanoBiodrugsTM
• Exhibit 64: Illustration of Starpharma's VivaGel™ In Proposed Single-use Applicator Exhibit 65: Interstitial NS Portable Personal Inhaler; Utilises SAW Delivery For Non-Invasive, Pain-Free, User-Controlled Delivery Of Large Molecule Drugs
• Exhibit 66: The Comparison Of Conventional Passive Technology And Biophan Active Technology By Using Nanomagnetic Technology
• Exhibit 67: Polymer Matrix
• Exhibit 68: Particles Loaded On Stent Coating
• Exhibit 69: Drugs Bound To Nanomagnetic Particles
• Exhibit 70: EM Signal Releasing Drugs
• Exhibit 71: Second EM Signal Releasing Drugs
• Exhibit 72: Features Of Nanocarrier's DDS Technologies
• Exhibit 73: The Core Technology - Micellar Nanoparticles
• Exhibit 74: NanoCarrier's Micellar Nanoparticles
• Exhibit 75: NanoCapTM
• Exhibit 76: MediCelleTM
• Exhibit 77: NanoCoat System
• Exhibit 78: Unique Benefit Of True Nanoparticles In Oncology: Targeting To Tumors
• Exhibit 79: Chemistry of ProLindac™
• Exhibit 80: Prolindac™ Releases Platinum Much More Rapidly In A Slightly Acidic Environment Compared With An Environment Of The Body's Normal
• Physiological pH
• Exhibit 81: Emulsiphan™ - Passive Targeting
• Exhibit 82: Emulsiphan™ - Active Targeting
• Exhibit 83: Insert Therapeutics' Cyclosert™ Technology
• Exhibit 84: A Photomicrograph Of A Nano-Composite Particle
• Exhibit 85: A Graphic Representation Of The Molecular Dot
• Exhibit 86: An Overview Of Some Features Of Molecular Dot
• Exhibit 87: Ceramide MDs Kill Drug-Resistant Breast Cancer Cells
• Exhibit 88: BioSante's Product Pipeline
• Exhibit 89: NanoMed's Nanotemplate Engineering Technology
• Exhibit 90: Confocal Pictures of DC's Starined Red With Anti-CD11c And Green Nanoparticles
• Exhibit 91: Novavax's Micellar Nano Particles (MNPs)
• Exhibit 92: The Comparison of Convential Antibody and Ablynx's Nanobody
• Exhibit 93: Nanoviricides Dismantling MCMV Seen In TEM
• Exhibit 94: Nanoviricides Product Illustration
• Exhibit 95: NanoViricides Product Pipeline
• Exhibit 96: How BNP Works
• Exhibit 97: AskBio's Product Pipeline
• Exhibit 98: Nature Compacts DNA
• Exhibit 99: RNA Interference ("RNAi")
• Exhibit 100: Calando's siRNA Technology
• Exhibit 101: Preclinical Data That Demonstrate Sequence-Specific Gene Inhibition In Tumors From The Systemic Administration Of Targeted Formulations Of Sirna .
• Exhibit 102: qRT-PCR Result Summary
• Exhibit 103: Layers/Functions Of Intradigm's Nanoparticle
• Exhibit 104: Intradigm Nanoparticle Delivery System for RNAi
• Exhibit 105: Potential Targets For Which Active Sirnas Have Been Identified
• Exhibit 106: Flamel's Unique Method For The Controlled Release Of Proteins And Peptides
• Exhibit 107: Flamel's MedusaR Technology
• Exhibit 108: Flamel's MedusaR Product Pipeline
• Exhibit 109: Novosom AG's SMARTICLESR
• Exhibit 110: An Animation Of The Process By Which SMARTICLESR Deliver DNA Based Therapeutics Inside A Cell
• Exhibit 111: Novosom's CAGICLESR
• Exhibit 112: NovaSOL Product Micelle
• Exhibit 113: AQUANOVA Solubilisates (Examples)
• Exhibit 114: AQUANOVA Capsules
• Exhibit 115: Bio Delivery Sciences International's BioralR Encochleation Drug Delivery Technology
• Exhibit 116: Determination Of Residual Moisture By Karl-Fischer-Methodd
• Exhibit 117: Overview Of The Encapsulation Process
• Exhibit 118: Overview Of The Complexation Process
• Exhibit 119: How Scalable Technology Addresses Industry's Key Problems In Biopharmaceutical Delivery
• Exhibit 120: Genesegues' Nanoencapsulated Therapeutic
• Exhibit 121: iCeutica's EON Process (Example)
• Exhibit 122: NutraLease's Nanoencapsulation Technology
• Exhibit 123: The Nano-Sized Self-Assembled Structured Liquids (NSSL) Technology
• Exhibit 124: A Phase Diagram Of The Possible Combinations To Form The Nano-Sized Self-Assembled Structured Liquids (NSSL)
• Exhibit 125: Nutralease's FNV technology
• Exhibit 126: The Release Of Nutralease' Nutraceuticals Into The Membrance Between The Digestive System And The Blood
• Exhibit 127: NutraLease Products
• Exhibit 128: Avidimer Therapeutics' Avidimers
• Exhibit 129: Illustration Of The Dendrimer Compared In Size To Hemoglobin
• Exhibit 130: Priostar™ Product Pipeline
• Exhibit 131: DNT's PrioFect™
• Exhibit 132: DNT's STARBURSTR Dendrimers
• Exhibit 133: An Example Of Phospholipase A2 Catalyzed Hydrolysis Of A Lipid Membrane Visualized By Atomic Force Microscopy
• Exhibit 134: NanoCyte mode of operation
• Exhibit 135: How Does Colloidal Gold Work
• Exhibit 136: CytImmune Product pipeline
• Exhibit 137: Molecular Therapeutics' Dynamic Nano-Platform
• Exhibit 138: Nanoedge Technology Features
• Exhibit 139: Nanoedge Solid Partilce Technologies
• Exhibit 140: How Do Labopharm's Polymeric Nano-Delivery System™ Work
• Exhibit 141: Labopharm's Technologies For In Vivo Delivery
• Exhibit 142: Labopharm's Therapeutic Pipeline
• Exhibit 143: Labopharm's Business Development
• Exhibit 144: Intezyne Technologies' IVECT™ Drug Delivery Platform
• Exhibit 145: Insert Therapeutics' Cyclosert™ Polymers
• Exhibit 146: Insert Therapeutics' Cyclosert™ Multiple Formulations